Cetek Corp.

With conventional drug screening technologies, for example, ELISA (enzyme-linked immunosorbent assays), cell-based assays, or receptor-binding assays, screeners often have to choose between high-throughput and high specificity. Cetek Corp. believes it has a new screening technology that does not require one to sacrifice speed for extremely precise information and vice versa. According to the company, its technology reveals binding affinity (how strong a hit is) and specificity early in the dereplication or scale up process. Its approach, Cetek claims, usually takes 2-8 weeks for assay development versus the 3-12 months it can take for typical assay development.

Cetek's drug screening platform, a technology licensed from Northeastern University 's Barnett Institute, combines laser-induced fluorescence with high-resolution capillary...